Cullinan Therapeutics (CGEM) Cash from Operations (2020 - 2023)
Historic Cash from Operations for Cullinan Therapeutics (CGEM) over the last 4 years, with Q4 2023 value amounting to -$18.1 million.
- Cullinan Therapeutics' Cash from Operations rose 2742.67% to -$18.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$134.3 million, marking a year-over-year decrease of 600.88%. This contributed to the annual value of -$145.3 million for FY2024, which is 821.3% down from last year.
- Cullinan Therapeutics' Cash from Operations amounted to -$18.1 million in Q4 2023, which was up 2742.67% from -$34.1 million recorded in Q3 2023.
- Cullinan Therapeutics' 5-year Cash from Operations high stood at -$1.5 million for Q1 2021, and its period low was -$54.4 million during Q3 2022.
- Moreover, its 4-year median value for Cash from Operations was -$17.2 million (2021), whereas its average is -$20.9 million.
- Per our database at Business Quant, Cullinan Therapeutics' Cash from Operations surged by 6979.06% in 2021 and then plummeted by 134607.26% in 2022.
- Over the past 4 years, Cullinan Therapeutics' Cash from Operations (Quarter) stood at -$9.4 million in 2020, then tumbled by 60.78% to -$15.2 million in 2021, then tumbled by 64.68% to -$25.0 million in 2022, then increased by 27.43% to -$18.1 million in 2023.
- Its Cash from Operations was -$18.1 million in Q4 2023, compared to -$34.1 million in Q3 2023 and -$31.0 million in Q2 2023.